Dapagliflozin Propanediol | ||||
CAS NO.: | 461432-26-8 | |||
Chemical Formula: | C21H25ClO6 | |||
Molecular Weight: | 408.8730 | |||
DMF&GMP status: | Please contact us for more details. | Description: |
Dapagliflozin is an oral diabetes medicine that helps control blood sugar levels. Dapagliflozin works by helping the kidneys get rid of glucose from your bloodstream. Dapagliflozin is used together with diet and exercise to treat type 2 diabetes. Dapagliflozin is not for treating type 1 diabetes. Dapagliflozin is indicated for the management of diabetes mellitus type 2, and functions to improve glycemic control in adults when combined with diet and exercise. Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor, which prevents glucose reabsorption in the kidney. Using dapagliflozin leads to heavy glycosuria (glucose excretion in the urine), which can lead to weight loss and tiredness. Dapagliflozin was approved by the FDA on Jan 08, 2014.
|
|
Approvals | ||||
Active Ingredient | Dosage Form; Route | Strength | Proprietary Name | Applicant |
DAPAGLIFLOZIN PROPANEDIOL | TABLET; ORAL | EQ 10MG BASE | FARXIGA | ASTRAZENECA AB |
DAPAGLIFLOZIN PROPANEDIOL | TABLET; ORAL | EQ 5MG BASE | FARXIGA | ASTRAZENECA AB |
DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE | TABLET; EXTENDED RELEASE; ORAL | EQ 10MG BASE; 1GM | XIGDUO XR | ASTRAZENECA AB |
DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE | TABLET; EXTENDED RELEASE; ORAL | EQ 10MG BASE; 500MG | XIGDUO XR | ASTRAZENECA AB |
DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE | TABLET; EXTENDED RELEASE; ORAL | EQ 5MG BASE; 1GM | XIGDUO XR | ASTRAZENECA AB |
DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHL | TABLET EXTENDED RELEASE; ORAL | EQ 5MG BASE; 500MG | XIGDUO XR | ASTRAZENECA AB |
Patent Data | ||||
Patent No. | Patent Expiration | Drug Substance Claim | Drug Product Claim | Patent Use Code |
6414126 | 4-Oct-20 | Y | Y | U - 493 |
6515117 | 4-Oct-20 | Y | Y | U - 493 |
6936590 | 4-Oct-20 | U - 493 | ||
7851502 | 19-Aug-28 | Y | ||
7919598 | 16-Dec-29 | Y | ||
8221786 | 21-Mar-28 | Y | ||
8361972 | 21-Mar-28 | U - 493 | ||
8501698 | 20-Jun-27 | Y | U - 493 | |
8685934 | 26-May-30 | U – 1522 | ||
8716251 | 21-Mar-28 | Y | ||
9198925 | 4-Oct-20 | U - 493 | ||
Exclusive Data | ||||
Exclusivity Code | Exclusivity Expiration | |||
NCE | 01/08/2019 | |||
M - 157 | 03/11/2018 | |||